A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study
Erica Brivio(Princess Máxima Center), C. Michel Zwaan(Princess Máxima Center), Cormac Ownes(Children's Health Ireland at Crumlin), Claudia Rössig(Klinik und Poliklinik für Kinder- und Jugendmedizin), Ingrid Øra(Karolinska University Hospital), Inge M. van der Sluis(Princess Máxima Center), Franco Locatelli(Bambino Gesù Children's Hospital), Christiane Chen‐Santel(Universitätsmedizin Rostock), Monique L. den Boer(Princess Máxima Center), Jan Starý(Charles University), Luciana Vinti(Bambino Gesù Children's Hospital), Anneke C. J. Ammerlaan(Princess Máxima Center), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Vincent van der Velden(Erasmus MC), Bella Bielorai, Karsten Nysom(Copenhagen University Hospital), Ying Chen(Pfizer (United States)), Marta López‐Yurda(The Netherlands Cancer Institute), Barbara Sleight(Pfizer (United States)), Benoît Brethon(Hôpital Saint-Louis)
Cited by 8
Related Papers
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term<i>In vitro</i>Culture and Do Not Exhibit Telomere Maintenance Mechanisms
|Cancer Research|2007|702
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
|New England Journal of Medicine|2004|645